Unique ID issued by UMIN | UMIN000025893 |
---|---|
Receipt number | R000029728 |
Scientific Title | Examination of the Effects of Long Pepper Extract on Blood Flow and Skin Surface Temperature Following the Exposure to Cold Water Stress: Placebo controlled, Randomized, Double-blind, Cross-over Study |
Date of disclosure of the study information | 2017/01/31 |
Last modified on | 2017/03/12 14:13:03 |
Examination of the Effects of Long Pepper Extract on Blood Flow and Skin Surface Temperature Following the Exposure to Cold Water Stress: Placebo controlled, Randomized, Double-blind, Cross-over Study
Examination of the Effects of Long Pepper Extract on Blood Flow and Skin Surface Temperature Following the Exposure to Cold Water Stress: Placebo controlled, Randomized, Double-blind, Cross-over Study
Examination of the Effects of Long Pepper Extract on Blood Flow and Skin Surface Temperature Following the Exposure to Cold Water Stress: Placebo controlled, Randomized, Double-blind, Cross-over Study
Examination of the Effects of Long Pepper Extract on Blood Flow and Skin Surface Temperature Following the Exposure to Cold Water Stress: Placebo controlled, Randomized, Double-blind, Cross-over Study
Japan |
N/A (healthy adults)
Adult |
Others
NO
This study examines the effects of long pepper extract on blood flow and skin surface temperature following the exposure to cold water stress.
Efficacy
[1]Blood flow measurement with laser doppler (First observation, Second observation)
[2]Skin surface temperature measurement with thermography (Screening, First observation, Second observation)
*Secondary outcomes
[1]Axillary temperature (Screening, First observation, Second observation)
[2]Doctor's questions (Screening, First observation, Second observation)
[3]Subject's diary(From the first day of ingestion of a test material to the last day of the test)
*Other indexes
[1]Height, weight, body fat percentage, BMI (Screening)
[2]Blood pressure (Screening)
[3]Subjective questionnaire on cold (Screening)
[4]Simplified Menopausal Index (Screening)
Interventional
Cross-over
Randomized
Individual
Double blind -all involved are blinded
Placebo
2
Treatment
Food |
[1]Oral intake of the test product (containing long pepper extract; 1 package in a day; 1 time)
[2]The exposure to cold water stress
[3]Observation
[4]Washout (1 week)
[5]Oral intake of the placebo product (not containing long pepper extract; 1 package in a day; 1 time)
[6]The exposure to cold water stress
[7]Observation
[1]Oral intake of the placebo product (not containing long pepper extract; 1 package in a day; 1 time)
[2]The exposure to cold water stress
[3]Observation
[4]Washout (1 week)
[5]Oral intake of the test product (containing long pepper extract; 1 package in a day; 1 time)
[6]The exposure to cold water stress
[7]Observation
20 | years-old | <= |
65 | years-old | > |
Female
[1]Japanese females aged 20-64 years.
[2]Individuals who are healthy.
[3]Individuals who are sensitive to cold.
[4]Individuals whose written informed consent has been obtained.
[5]Individuals judged appropriate for the study by the principal.
[1]Individuals using medical products.
[2]Individuals who used a drug to treat a disease in the past 1 month (except temporal usage for pollenosis).
[3]Individuals who use a drug to treat a disease.
[4]Individuals who were an asthmatic patient in the past 3 months or is an asthmatic patient.
[5]Individuals with serious anemia.
[6]Individuals who are sensitive to a test product or other foods, and medical products.
[7]Individuals who had a habit to ingest health-promoting foods, foods for specified health uses, health foods, or supplements in the past 3 months or will ingest those foods during the test period.
[8]Individuals with serious diseases (ex. diabetes, hepatopathy disease, kidney damage, heat failure, endocrine disease), or who are a patient of or have a history of thyroid disease, adrenal disease, metabolic disease).
[9]Individuals who conducted hormone replacement therapy in the past 3 months or have a history of conducting hormone replacement therapy.
[10]Individuals who have an inflammation or a scar on a measuring area.
[11]Individuals whose systolic blood pressure is over 160mmHg or diastolic pressure is over 100mmHg.
[12]Individuals who excessively take alcohol (expressed in an amount of alcohol: over 60mg/day).
[13]Individuals who donated blood over 200mL in the past 1 month or over 400mL in the past 3 months.
[14]Individuals who are a smoker.
[15]Individuals who participated in other clinical studies in the past 3 months.
[16]Individuals whose Simplified Menopausal Index score is over 51.
[17]Individuals who have a history of ovarian resection or hysterectomy.
[18]Individuals who are or are possibly, or are lactating.
[19]Individuals judged inappropriate for the study by the principal.
30
1st name | |
Middle name | |
Last name | Shuji Nakata |
Medical Corporation Bokushinkai CLINTEXE Clinic
Director
4F Atago Green Hills Mori Tower 2-5-1 Atago Minato-ku Tokyo 105-6204, JAPAN
03-5405-1059
info@tes-h.co.jp
1st name | |
Middle name | |
Last name | Ryoma Shimizu |
TES Holdings Co., Ltd
Administrative Department of Clinical Trials
6F University of Tokyo Entrepreneur Plaza 7-3-1 Hongo Bunkyo-ku Tokyo 113-0033, JAPAN
03-6801-8480
r.shimizu@tes-h.co.jp
TES Holdings Co., Ltd.
Maruzen Pharmaceuticals Co., Ltd.
Profit organization
NO
2017 | Year | 01 | Month | 31 | Day |
Unpublished
Completed
2017 | Year | 01 | Month | 16 | Day |
2017 | Year | 02 | Month | 09 | Day |
2017 | Year | 01 | Month | 29 | Day |
2017 | Year | 03 | Month | 12 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000029728